Contrast Induced Nephropathy
|
|
- Cameron Gilbert
- 6 years ago
- Views:
Transcription
1 Contrast Induced Nephropathy
2 O CIAKI refers to an abrupt deterioration in renal function associated with the administration of iodinated contrast media O CIAKI is characterized by an acute (within 48 hours) 0.3 mg/dl or 50% increase in baseline SCr, or a reduction in urine output to <0.5 ml/kg per hour for more than 6 hours (Acute Kidney Injury Network) Journal of Nephrology 2010; 23(04):
3 O A more common definition is 0.5 mg/dl or 25% increase in baseline SCr within 3 days of intravascular CM exposure, in the absence of an alternative etiology O The SCr increase peaks between days 3 and 5 with levels usually returning to baseline within 1 to 3 weeks
4 Increasing risk O Technological advances in imaging modalities, expanding imaging application cardiology patients undergoing invasive coronary angiography and/or PCI Interventional radiology patients undergoing different procedures patients from a variety of different specialties undergoing diagnostic CT O And an aging world population Journal of Nephrology 2010; 23(04):
5 Associated with O increased morbidity and mortality O longer hospital stays O higher rates of in-hospital events; O higher rates of in-hospital 1-year and 5-year mortality Journal of Nephrology 2010; 23(04):
6 Risk factors O CKD particularly CKD combined with diabetes mellitus DM O Advanced age O Metabolic syndrome O Prediabetes O Hyperuricemia O Hypertriglyceridemia O Impaired fasting glucose O Gender (women 65 years of age are at greater risk than their male counterparts) O Intra-arterial contrast administration Journal of Nephrology 2010; 23(04):
7 Pathogenesis
8 O Contrast media causes direct injury to the cells lining the renal tubule O The injury can be reproduced in vitro by incubating cells of the proximal tubule with contrast media O Cell death begins within minutes of exposure O The contrast media is taken up into the cells and alters mitochondrial function resulting in generation of reactive oxygen species and apoptosis Radiologic Clinics of North America Volume 47, Issue 5, September 2009
9 O This injury is exacerbated by a simultaneous reduction in medullary blood flow that occurs in vivo resulting from vasoconstriction of the vasa recta O The medulla of the kidney has both very high oxygen consumption supporting active sodium transport and low tissue oxygen levels O Critical tissue hypoxia results following contrast media leading to additional damage of tubule cells within this region of the kidney Radiologic Clinics of North America Volume 47, Issue 5, September 2009
10 Investigative Radiology Volume 45, Number 4, April 2010
11 Incidence
12 The American Journal of Cardiology Volume 98, 18 September 2006
13 The American Journal of Cardiology Volume 98, 18 September 2006
14 Incidence in outpatients O O O O O A prospective, consecutive cohort (June 2007 through January 2009) of patients who received intravenous contrast for CECT in the emergency department of a large, academic, tertiary care center was enrolled The incidence of CIN was 11% (70 of 633) among the 633 patients enrolled Fifteen (2%) patients died within 45 d, including six deaths after study-defined CIN Seven (1%) patients developed severe renal failure, six of whom had study-defined CIN Of the six patients with CIN and severe renal failure, four died, and adjudicators determined that renal failure significantly contributed to all four deaths. Mitchell et al. CJASN January 2010 Vol 5
15 ACE inh and ARB O Four hundred twelve patients were included in a prospective, single-center study (January 2001 July 2004) to compare different treatments for CIN prevention O Creatinine levels within 72 h after CM application and in-hospital outcomes were documented Kiski D et al. Nephrol. Dial. Transplant. 2010;25:
16 Kiski D et al. Nephrol. Dial. Transplant. 2010;25:
17 Prevention
18 Contrast media Type of contrast
19 CONTRAST EXPOSURE Increased Viscosity Depends on Monomer vs Dimer forms Direct Vasoconstriction ISCHEMIA Increased Adenosine DIRECT CELLULAR TOXICITY Free Radical Formation Mitochondrial Toxicity Depends on Ionization Cell Vacuolization Depends on Osmolarity
20 Osmolarity Davidson et al (2006) Am J Cardiol 98(supp 6):42-58
21 Circulation: Cardiovascular Interventions. 3(4): , August 2010.
22 Circulation: Cardiovascular Interventions. 3(4): , August 2010
23 Contrast Media Dose of contrast
24 O Consecutive patients undergoing PCI were prospectively enrolled in the Dartmouth Dynamic Registry from 2000 to 2008 (n=10065) O Patients with preexisting dialysis-dependent renal failure were excluded (n=155) O Maximal acceptable contrast dose (MACD) was defined as (5 ml body weight [kg])/baseline serum creatinine [mg/dl] Circulation: Cardiovascular Interventions Volume 3(4), August 2010
25 Final model included age, sex, body surface area, diabetes, hypertension, congestive heart failure, chronic obstructive pulmonary disease, priority of PCI, number of stents inserted, and baseline estimated glomerular filtration rate using MDRD equation Circulation: Cardiovascular Interventions Volume 3(4), August 2010
26 CONTRAST EXPOSURE Increased Viscosity Pre-Hydration Direct Vasoconstriction ISCHEMIA Increased Adenosine -Theophylline Mitochondrial Toxicity -Dialysis DIRECT CELLULAR TOXICITY Cell Vacuolization Free Radical Formation -N Acetyl Cysteine -Bicarbonate
27 Volume expansion
28 Group 1 subjects (n = 27) received 0.9% saline for 24 h at a rate of 1 ml/kg/h beginning 12 h prior to scheduled catheterization; and group 2 subjects (n = 27) were allowed unrestricted oral fluids Nephron Clin Pract. 2003;93:C29 C34
29 A total of 1620 patients scheduled for elective or emergency coronary angioplasty were randomly assigned to receive isotonic (0.9% saline) (n = 809) or half-isotonic (0.45% sodium chloride plus 5% glucose) (n = 811) hydration beginning the morning of the procedure for elective interventions and immediately before emergency interventions. IV fluids were started at a rate of 1 ml/kg of body weight per hour at 8 AM on the day of coronary angioplasty or immediately on arrival in the catheter laboratory in case of emergency procedures. After the procedure, hydration was continued at 1 ml/kg of body weight per hour until 8 AM the next morning. Arch Intern Med. 2002;162:
30 Bicarbonate
31 Zoungas S et al. Ann Intern Med 2009;151:
32 Zoungas S et al. Ann Intern Med 2009;151:
33 Zoungas S et al. Ann Intern Med 2009;151:
34 Zoungas S et al. Ann Intern Med 2009;151:
35 N Acetylcysteine
36 Kelly A M et al. Ann Intern Med 2008;148:
37 Kelly A M et al. Ann Intern Med 2008;148:
38 O 354 consecutive patients undergoing primary angioplasty were randomized to one of three groups: 116 patients were assigned to a standard dose of N-acetylcysteine (a 600-mg intravenous bolus before primary angioplasty and 600 mg orally twice daily for the 48 hours after angioplasty) 119 patients to a double dose of N-acetylcysteine (a 1200-mg intravenous bolus and 1200 mg orally twice daily for the 48 hours after intervention) 119 patients to placebo N Engl J Med 2006; 354:
39 O In a study presented at the American Heart Association's annual meeting 2,308 patients undergoing an angiographic procedure were randomized to 1,200 mg of N-acetylcysteine, prescribed orally twice daily, with two doses given before the procedure and two doses after the procedure, or to placebo O There was no difference in the primary end point of contrast-induced nephropathy and no difference in the secondary end point of serum creatinine elevations
40 Renal Replacement Therapy
41 O It has been shown that dialysis removes contrast O However earlier trials have not been able to show any benefit to dialyze patients after administration of contrast O Dialysis was attempted at different times 1, 1.8 and 2 hours after contrast administration and in one study it was performed during the procedure itself O Some of those trials even showed worse kidney outcomes with dialysis
42
43 Dialysis Group (n = 42) Control Group (n = 40) p Value Age (yrs) 65.3 ± ± Male 27 (64%) 26 (65%) Body weight (kg) 63.7 ± ± Systemic hypertension 40 (95%) 37 (93%) Diabetes mellitus 23 (55%) 25 (62%) Coronary artery disease Stenosis <50% 3(7%) 1(3%) Single-vessel 16 (38%) 12 (30%) Double-vessel 8(19%) 10 (25%) Triple-vessel 15 (36%) 17 (42%) Prior myocardial infarction 10 (24%) 7(18%) Left ventricular ejection fraction 0.45± ± Use of ACE inhibitors 11 (26%) 11 (28%) Indication for CAG Stable angina 22 (52%) 22 (53%) Acute coronary syndrome 20 (48%) 18 (47%) Performed procedure Coronary angiography 19 (45%) 19 (47%) Percutaneous coronary intervention 22 (55%) 21 (53%) Volume of contrast medium (ml) ± ± Journal of the American College of Cardiology Volume 50, Issue 11, 11 September 2007
44 O All patients were given intravenous normal saline at 1 ml/kg/h for 6 h before and 12 h after contrast medium exposure, and then randomized to receive hemodialysis (dialysis group) or not (control group) O In the dialysis group, dialysis was started as soon as technically possible after angiography, and the time interval from contrast exposure to initiation of dialysis was recorded O The duration of dialysis was 4 h O To lessen the hemodynamic changes, 200 ml normal saline priming was administered before dialysis and no fluid removal was prescribed in the dialysis group Journal of the American College of Cardiology Volume 50, Issue 11, 11 September 2007
45 Changes from baseline in the Cr level were significant at the peak value in the dialysis group (***p = 0.008) and on day 4, at the peak value, and at discharge in the control group (*p < 0.001); the difference between the 2 groups was significant on day 4 and at peak value (**p = on day 4; p = at peak value) Journal of the American College of Cardiology Volume 50, Issue 11, 11 September 2007
46 Journal of the American College of Cardiology Volume 50, Issue 11, 11 September 2007
47 Marenzi et al. N Engl J Med Oct 2;349
48 O O O O Patients were assigned to receive either hemofiltration therapy in ICU (hemofiltration group) or intravenous hydration with isotonic saline given in a step-down unit (control group) For patients in the hemofiltration group, a treatment session was started 4 to 6 hours before the scheduled coronary procedure; treatment was resumed after the procedure was completed and continued for 18 to 24 hours The flow of isotonic replacement fluid was set at a rate of 1000 ml per hour and was exactly matched with the rate of ultrafiltrate production, so that no net fluid loss resulted Patients in the control group received a continuous intravenous infusion of isotonic saline at a rate of 1 ml per kilogram of body weight per hour for 6 to 8 hours before and 24 hours after the coronary procedure Marenzi et al. N Engl J Med Oct 2;349
49 Temporary renalreplacement therapy was required in 25 % of the control patients and in 3 % of the patients in the hemofiltration group The rate of in-hospital events was 9 % in the hemofiltration group and 52% in the control group (P<0.001) In-hospital mortality was 2% in the hemofiltration group and 14% in the control group (P=0.02) The cumulative one-year mortality was 10 % and 30%, respectively (P=0.01) Marenzi et al. N Engl J Med Oct 2;349
50 Controls (n = 30) Post-hemofiltration (n = 31) Pre/post hemofiltration (n = 31) P value Age (y) 71±6 72±8 72±7.86 Men 22 (73%) 23 (74%) 20 (65%).65 Weight (kg) 71±8 73±9 68±7.12 Diabetes 12 (40%) 9(29%) 7(23%).86 Hypertension 18 (60%) 21 (68%) 23 (74%).50 Prior MI 8(27%) 13 (42%) 10 (32%).44 Prior CABG 3(10%) 5(16%) 4(13%).77 Prior PCI 2(7%) 2(6%) 1(3%).80 Prior CHF 5(17%) 9(29%) 6(19%).47 Mean LVEF (%) 47±10 46±12 48±12.66 LVEF < 40% 9(30%) 12 (39%) 8(26%).24 Peripheral arterial disease 9(30%) 9(29%) 10 (32%).96 Cerebral vascular disease 4(13%) 4(13%) 5(16%).92 COPD 5(17%) 4(13%) 4(13%).89 Chronic atrial fibrillation 4(13%) 3(10%) 2(6%).66 Aspirin 15 (50%) 19 (61%) 13 (42%).31 ACE inhibitor or ARB 9(30%) 10 (32%) 8(26%).85 Diuretics 17 (57%) 20 (64%) 18 (58%).80 Indication for angiography Stable angina 10 (33%) 8(26%) 9(29%).81 Recent MI 4(13%) 7(23%) 6(19%).64 Unstable angina 9(30%) 10 (32%) 8(26%).85 Other 7(23%) 6(19%) 7(23%).92 Serum creatinine (mg/dl) 3.6± ± ± Creatinine clearance (ml/min) 20±5 20±4 18±4.12 Marenzi et al. Am J Med Feb;119(2)
51 Patients were randomized in a 1:1:1 ratio to receive 1 of the following 3 prophylactic treatments: intravenous hydration with isotonic saline, performed for 12 hours before and for 12 hours after contrast agent exposure (control group) intravenous hydration with isotonic saline, performed for 12 hours before contrast agent administration, followed by hemofiltration treatment for 18 to 24 hours after contrast agent exposure (post-hemofiltration group) hemofiltration treatment performed for 6 hours before and for 18 to 24 hours after contrast agent exposure (pre/post-hemofiltration group)
52 Marenzi et al. Am J Med Feb;119(2)
53 Controls (n = 30) Post hemofiltration (n = 31) Pre/post hemofiltration (n = 31) Acute myocardial infarction 5(17%) 4(13%) 1(3%).21 Emergency CABG 0(0%) 0(0%) 0(0%) - p value Pulmonary edema requiring MV Cardiogenic shock requiring IABP 1(3%) 1(3%) 0(0%).59 1(3%) 0(0%) 0(0%).35 Blood transfusion 4(13%) 6(19%) 5(16%).81 ARF requiring RRT 9(30%) 3(10%) 0(0%) clinical complications In-hospital mortality 6(20%) 2(6%) 0(0%).019 6(20%) 3(10%) 0(0%).02 Marenzi et al. Am J Med Feb;119(2)
54 Weisbord, ASN renal week, Denver, Co November 2010
55 Weisbord, ASN renal week, Denver, Co November 2010
SAFETY IN THE CATH LAB How to Minimise Contrast Toxicity
SAFETY IN THE CATH LAB How to Minimise Contrast Toxicity Dr. Vijay Kunadian MBBS, MD, MRCP Senior Lecturer and Consultant Interventional Cardiologist Institute of Cellular Medicine, Faculty of Medical
More informationPrevention of Contrast induced Nephropathy
55 th Annual Scientific Meeting of The Korean Society of Cardiology 11:50 12:10 Message from Nephrologists Dec 03, 2011 Prevention of Contrast induced Nephropathy Soo Wan Kim, MD, PhD Department of Internal
More informationContrast-Induced Nephropathy: Evidenced Based Prevention
Contrast-Induced Nephropathy: Evidenced Based Prevention Michael J Cowley, MD, FSCAI Nothing to disclose Contrast-Induced Nephropathy (CIN) Definitions New onset or worsening of renal function after contrast
More informationMinimizing the Renal Toxicity of Iodinated Contrast
Minimizing the Renal Toxicity of Iodinated Contrast Peter A. McCullough, MD, MPH, FACC, FACP, FAHA, FCCP Chief Academic and Scientific Officer St. John Providence Health System Detroit, MI USA Outline
More informationCATH LAB SYMPOSIUM 2010
CATH LAB SYMPOSIUM 2010 Low resistance system High Pressure in Capillaries to filter plasma RBF: 1.2-1.3 L/min (25% of C.O.) Low AV difference ( shunt ) Kidney: 14 ml O2/L blood Brain: 62 ml O2/L blood
More informationDoreen P. Foley MS RN ANP-C Doctor of Nursing Practice Program Chamberlain College of Nursing
Doreen P. Foley MS RN ANP-C Doctor of Nursing Practice Program Chamberlain College of Nursing This program has been developed solely for the purposes of describing the level of nurse practitioner (NP)
More information16/05/2018 NEFROPATIA DA MEZZO DI CONTRASTO: ANCORA UNA VECCHIA NEMICA?
16/05/2018 NEFROPATIA DA MEZZO DI CONTRASTO: ANCORA UNA VECCHIA NEMICA? Dott. Andrea Boccatonda Università degli Studi G. d Annunzio Chieti Chi di voi non ha mai discusso con un radiologo per eseguire
More informationOptimal Use of Iodinated Contrast Media In Oncology Patients. Focus on CI-AKI & cancer patient management
Optimal Use of Iodinated Contrast Media In Oncology Patients Focus on CI-AKI & cancer patient management Dr. Saritha Nair Manager-Medical Affairs-India & South Asia GE Healthcare Context Cancer patients
More informationSection 3: Prevention and Treatment of AKI
http://www.kidney-international.org & 2012 KDIGO Summary of ommendation Statements Kidney International Supplements (2012) 2, 8 12; doi:10.1038/kisup.2012.7 Section 2: AKI Definition 2.1.1: AKI is defined
More informationSafety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD
Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD Mun K. Hong, MD Associate Professor of Medicine Director, Cardiovascular Intervention and Research Weill Cornell
More informationAlex versus Xience Registry Preliminary report
Interventional Cardiology Network Alex versus Xience Preliminary report Mariusz Gąsior 1,2, Marek Gierlotka 1, Lech Poloński 1,2 1 3rd Department of Cardiology, Medical University of Silesia Centre tor
More informationMedical Management of Acute Heart Failure
Critical Care Medicine and Trauma Medical Management of Acute Heart Failure Mary O. Gray, MD, FAHA Associate Professor of Medicine University of California, San Francisco Staff Cardiologist and Training
More informationPivotal Role of Renal Function in Acute Heart failure
Pivotal Role of Renal Function in Acute Heart failure Doron Aronson MD, FESC Department of Cardiology RAMBAM Health Care Campus Haifa, Israel Classification and definitions of cardiorenal syndromes CRS
More informationThe MAIN-COMPARE Study
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationFluid Resuscitation in Critically Ill Patients with Acute Kidney Injury (AKI)
Fluid Resuscitation in Critically Ill Patients with Acute Kidney Injury (AKI) Robert W. Schrier, MD University of Colorado School of Medicine Denver, Colorado USA Prevalence of acute renal failure in Intensive
More informationA Paradigm Shift in Contrast-Induced Acute Kidney Injury (CI-AKI) Prevention
CE Mark US: Investigational device. Limited by Federal Law to investigational use only. A Paradigm Shift in Contrast-Induced Acute Kidney Injury (CI-AKI) Prevention 1 ED00092 Rev. A Clinical Problem 2
More informationCTA in acute stroke assessment
CTA in acute stroke assessment Assumptions: It is more efficient to cancel an unnecessary CTA than to order a CTA after the fact It is more efficient to make 1 trip to the CT scanner Even if no LVO, CTA
More informationJin Wi, 1 Young-Guk Ko, 1 Jung-Sun Kim, 1 Byeong-Keuk Kim, 1 Donghoon Choi, 1 Jong-Won Ha, 1 Myeong-Ki Hong, 1,2 Yangsoo Jang 1,2 ORIGINAL ARTICLE
See Editorial, p 1723 1 Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Republic of Korea 2 Severance Biomedical Science Institute, Yonsei University
More informationGuidelines on the Use of Iodinated Contrast Media in Patients With Kidney Disease 2012
Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp JCS GUIDELINES Guidelines on the Use of Iodinated Contrast Media in Patients With Kidney Disease 2012 Digest
More informationProtocol for iv. iodine and gadolinium contrast studies
Protocol for iv. iodine and gadolinium contrast studies Royal College of Radiologists Standard The individual administering the contrast agent must ensure that the patient understands that it is to be
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Table S1: Number and percentage of patients by age category Distribution of age Age
More informationN-acetylcysteine in the prevention of contrast agent-induced nephrotoxicity in patients undergoing computed tomography studies
RESEARCH REPORT N-acetylcysteine in the prevention of contrast agent-induced nephrotoxicity in patients undergoing computed tomography studies Hossein Khalili, Simin Dashti-Khavidaki, Hamed Tabifar, Nasrin
More informationUpdate in Nephrology. Case: Question 1. Case presentation. Acute Kidney Injury. For her hypertension management, you decide to:
Update in Nephrology Chronic Kidney Disease Renoprotection and Proteinuria, ACE and/or ARB Anemia management Update in Nephrology Renal artery stenosis Nephrogenic systemic fibrosis Division of Nephrology
More informationThe MAIN-COMPARE Registry
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationPROMUS Element Experience In AMC
Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,500 108,000 1.7 M Open access books available International authors and editors Downloads Our
More informationSofia Fayngold CRC Rotation IRB proposal 9/1/2011
Sofia Fayngold CRC Rotation IRB proposal 9/1/2011 Sodium Bicarbonate Hydration for the Prevention of Contrast Induced Nephropathy following Computed Tomography Angiography of the Chest for Pulmonary Emoblism
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,000 116,000 120M Open access books available International authors and editors Downloads Our
More informationHeart failure hospitalizations with preserved or reduced ejection fraction
Clinical profile and in-hospital outcomes in patients admitted for heart failure with preserved or reduced ejection fraction. EPI-CARDIO prospective registry Tajer, C; Mariani, J; de Abreu, M; Charask,
More informationAcute kidney injury and outcomes in acute decompensated heart failure in Korea
Acute kidney injury and outcomes in acute decompensated heart failure in Korea Mi-Seung Shin 1, Seong Woo Han 2, Dong-Ju Choi 3, Eun Seok Jeon 4, Jae-Joong Kim 5, Myeong-Chan Cho 6, Shung Chull Chae 7,
More informationAssessing Cardiac Risk in Noncardiac Surgery. Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington
Assessing Cardiac Risk in Noncardiac Surgery Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington Disclosure None. I have no conflicts of interest, financial or otherwise. CME
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationRevascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease
Impact of Angiographic Complete Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease Young-Hak Kim, Duk-Woo Park, Jong-Young Lee, Won-Jang
More informationProgram Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name
Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for, Atrial Fibrillation, Hypertension and.
More informationCardiogenic Shock. Carlos Cafri,, MD
Cardiogenic Shock Carlos Cafri,, MD SHOCK= Inadequate Tissue Mechanisms: Perfusion Inadequate oxygen delivery Release of inflammatory mediators Further microvascular changes, compromised blood flow and
More informationHeart Failure and Renal Failure. Gerasimos Filippatos, MD, FESC, FHFA President HFA
Heart Failure and Renal Failure Gerasimos Filippatos, MD, FESC, FHFA President HFA Definition Epidemiology Pathophysiology Management (?) Recommendations for NHLBI in cardiorenal interactions related to
More informationThe PRESERVE trial: does it guide prevention strategies for post angiography acute kidney injury?
Editorial Page 1 of 7 The PRESERVE trial: does it guide prevention strategies for post angiography acute kidney injury? Richard Solomon Larner College of Medicine, University of Vermont, Burlington, VT,
More informationLearning Objectives. How big is the problem? ACUTE KIDNEY INJURY
ACUTE KIDNEY INJURY Karen Innocent, DNP, RN, CRNP, ANP-BC, CMSRN Executive Director, Continuing Education Wolters Kluwer Health, Inc May 2016 Orlando FL Learning Objectives Identify the risk factors and
More informationFFR Incorporating & Expanding it s use in Clinical Practice
FFR Incorporating & Expanding it s use in Clinical Practice Suleiman Kharabsheh, MD Consultant Invasive Cardiology Assistant professor, Alfaisal Univ. KFHI - KFSHRC Concept of FFR Maximum flow down a vessel
More informationCurrent Role of Renal Artery Stenting in Patients with Renal Artery Stenosis
Current Role of Renal Artery Stenting in Patients with Renal Artery Stenosis Young-Guk Ko, M.D. Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea Etiology Fibromuscular
More informationJun-Won Lee, Sang Wook Park, Jung-Woo Son, Young Jin Youn, Min-Soo Ahn, Sung Gyun Ahn, Jang-Young Kim, Byung-Soo Yoo, Junghan Yoon, Seung-Hwan Lee
The procedural success and complication rate of the left distal radial approach for coronary angiography and percutaneous coronary intervention. Prospective observational study (LeDRA) Jun-Won Lee, Sang
More informationConsensus Core Set: Cardiovascular Measures Version 1.0
Consensus Core Set: Cardiovascular s NQF 0330 Hospital 30-day, all-cause, riskstandardized readmission rate (RSRR) following heart failure hospitalization 0229 Hospital 30-day, all-cause, riskstandardized
More informationCKD FOR INTERNISTS. Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College
CKD FOR INTERNISTS Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College INTRODUCTION In 2002, the National Kidney Foundation s Kidney Disease Outcomes Quality Initiative(KDOQI)
More informationPrevention of Acute Renal Failure Role of vasoactive drugs and diuretic agents
of Acute Renal Failure Role of vasoactive drugs and diuretic agents Armand R.J. Girbes Prof.dr. A.R.J. Girbes Chairman department of Intensive Care VU University Medical Center Netherlands (Failure of)
More informationCardiorenal Syndrome: What the Clinician Needs to Know. William T. Abraham, MD Director, Division of Cardiovascular Medicine
Cardiorenal Syndrome: What the Clinician Needs to Know William T. Abraham, MD Director, Division of Cardiovascular Medicine Orlando, Florida October 7-9, 2011 Renal Hemodynamics in Heart Failure Glomerular
More informationTAVR in patients with. End-Stage CKD or in Renal Replacement Therapy:
TAVR in patients with End-Stage CKD or in Renal Replacement Therapy: Special Considerations and Prevention of early Valve Failure Antonios Chalapas, MD, PhD, FESC THV & Hygeia Hospital Heart Team Athens,
More informationCan We Achieve Precision Solute Control with CRRT?
Can We Achieve Precision Solute Control with CRRT? Claudio Ronco, M.D. David Selewski, M.D. Rolando Claure-Del Granado, M.D. AKI & CRRT Conference February, 2019 Disclosures I have no actual or potential
More informationCorrespondence should be addressed to Lantam Sonhaye;
Radiology Research and Practice Volume 2015, Article ID 805786, 4 pages http://dx.doi.org/10.1155/2015/805786 Research Article Intravenous Contrast Medium Administration for Computed Tomography Scan in
More informationManagement of stable CAD FFR guided therapy: the new gold standard
Management of stable CAD FFR guided therapy: the new gold standard Suleiman Kharabsheh, MD Director; CCU, Telemetry and CHU Associate professor of Cardiology, Alfaisal Univ. KFHI - KFSHRC Should patients
More informationEffect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
More informationCardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003
Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,
More informationNon ST Elevation-ACS. Michael W. Cammarata, MD
Non ST Elevation-ACS Michael W. Cammarata, MD Case Presentation 65 year old man PMH: CAD s/p stent in 2008 HTN HLD Presents with chest pressure, substernally and radiating to the left arm and jaw, similar
More informationAcute Coronary Syndrome. Sonny Achtchi, DO
Acute Coronary Syndrome Sonny Achtchi, DO Objectives Understand evidence based and practice based treatments for stabilization and initial management of ACS Become familiar with ACS risk stratification
More information03/07/ Background. + High Risk Features Are Prevalent in Dialysis Patients
+ When Does Cardiovascular Disease Preclude Consideration of Renal Transplantation? Kul Aggarwal, MD, MRCP (UK), FACC Professor of Clinical Medicine Division of Cardiology University of Missouri & Chief,
More informationLe# main treatment with Stentys stent. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy
Le# main treatment with Stentys stent Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy Disclosure Statement of Financial Interest I, Carlo Briguori DO NOT have a financial interest/ arrangement
More informationCONTRAST-INDUCED NEPHROPATHY Y HỌC CHỨNG CỨ VÀ BIỆN PHÁP DỰ PHÒNG
CONTRAST-INDUCED NEPHROPATHY Y HỌC CHỨNG CỨ VÀ BIỆN PHÁP DỰ PHÒNG DEFINITION Reversible form of acute kidney injury that occurs soon after the administration of radiocontrast media. PATHOGENESIS RISK FACTORS
More informationFollow-up of patients with contrast-induced nephropathy
http://www.kidney-international.org & 2006 International Society of Nephrology Follow-up of patients with contrast-induced nephropathy R Solomon 1 and B Barrett 2 1 Fletcher Allen Health Care, University
More informationNon-pharmacological Strategies to Prevent Kidney Injury in Patients Undergoing Contrast Media Exposure Eugenia Nikolsky, MD, PhD, FACC, FESC
Non-pharmacological Strategies to Prevent Kidney Injury in Patients Undergoing Contrast Media Exposure Eugenia Nikolsky, MD, PhD, FACC, FESC Rambam Health Care Campus Technion - Israel Institute of Technology
More informationLife After CORAL: What Did CORAL Prove? David Paul Slovut, MD, PhD Co-director TAVR, Dir of Advanced Intervention
Life After CORAL: What Did CORAL Prove? David Paul Slovut, MD, PhD Co-director TAVR, Dir of Advanced Intervention No Relationships to Disclose The Need for Modern Renal Trials Increased rate of RAS diagnosis
More informationCatheter-based mitral valve repair MitraClip System
Percutaneous Mitral Valve Repair: Results of the EVEREST II Trial William A. Gray MD Director of Endovascular Services Associate Professor of Clinical Medicine Columbia University Medical Center The Cardiovascular
More informationAssessment of estimated GFR and clinical predictors of contrast induced nephropathy among diabetic patients undergoing cardiac catheterization
The Egyptian Heart Journal (2015) 67, 249 258 HOSTED BY Egyptian Society of Cardiology The Egyptian Heart Journal www.elsevier.com/locate/ehj www.sciencedirect.com ORIGINAL ARTICLE Assessment of estimated
More informationCRRT for the Experience User 1. Claudio Ronco, M.D. David Selewski, M.D. Rolando Claure-Del Granado, M.D. AKI & CRRT Conference March, 2018
CRRT for the Experience User 1 Claudio Ronco, M.D. David Selewski, M.D. Rolando Claure-Del Granado, M.D. AKI & CRRT Conference March, 2018 Disclosures I have no actual or potential conflict of interest
More informationof developing contrast -induced
Original Article Singapore Med 1 2009, 50 (3) : 250 Diabetic patients with normal baseline renal function are at increased risk of developing contrast -induced nephropathy post-percutaneous coronary intervention
More informationPractice-Level Executive Summary Report
PINNACLE Registry Metrics 0003, Test Practice_NextGen [Rolling: 1st April 2015 to 31st March 2016 ] Generated on 5/11/2016 11:37:35 AM American College of Cardiology Foundation National Cardiovascular
More informationCoronary Artery Stenosis. Insight from MAIN-COMPARE Study
PCI for Unprotected Left Main Coronary Artery Stenosis Insight from MAIN-COMPARE Study Young-Hak Kim, MD, PhD Cardiac Center, University of Ulsan College of Medicine, Asan Medical Center Current Practice
More informationResearch Article Changes in Renal Function in Elderly Patients Following Intravenous Iodinated Contrast Administration: A Retrospective Study
Radiology Research and Practice, Article ID 459583, 4 pages http://dx.doi.org/10.1155/2014/459583 Research Article Changes in Renal Function in Elderly Patients Following Intravenous Iodinated Contrast
More informationCORONARY ARTERY BYPASS GRAFT (CABG) MEASURES GROUP OVERVIEW
CONARY ARTERY BYPASS GRAFT (CABG) MEASURES GROUP OVERVIEW 2015 PQRS OPTIONS F MEASURES GROUPS: 2015 PQRS MEASURES IN CONARY ARTERY BYPASS GRAFT (CABG) MEASURES GROUP: #43 Coronary Artery Bypass Graft (CABG):
More informationThe pathophysiology of contrast medium induced nephropathy
The pathophysiology of contrast medium induced nephropathy Peter Aspelin Professor of Radiology Karolinska Institutet 5th Nordic Course in Emergency Radiology, Oslo 2015 Background Contrast medium-induced
More informationEvaluating the Efficacy of Single Daily Dose of 1200mg of N-Acetyl-Cysteine in Preventing Contrast Agent-Associated Nephrotoxicity
ISPUB.COM The Internet Journal of Internal Medicine Volume 6 Number 1 Evaluating the Efficacy of Single Daily Dose of 1200mg of N-Acetyl-Cysteine in Preventing Contrast Agent-Associated Nephrotoxicity
More informationPerformance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set
Unless indicated, the PINNACLE Registry measures are endorsed by the American College of Cardiology Foundation and the American Heart Association and may be used for purposes of health care insurance payer
More informationUseful? Definition of High-risk? Pre-OP/Intra-OP/Post-OP? Complication vs Benefit? Mortality? Morbidity?
Preoperative intraaortic balloon counterpulsation in high-risk CABG Stefan Klotz, M.D. Preoperative IABP in high-risk CABG Questions?? Useful? Definition of High-risk? Pre-OP/Intra-OP/Post-OP? Complication
More informationProtocol. This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Weisbord SD, Gallagher M, Jneid H, et al. Outcomes after angiography
More informationVersion 4.4. Institutional Outcomes Report 2014Q3. National Outcomes Report Aggregation Date: Jan 12, :59:59 PM
Version 4.4 Institutional Outcomes Report 2014Q3 National Outcomes Report 999997 Aggregation Date: Jan 12, 2015 11:59:59 PM Publish Date: Jan 29, 2015 If User desires to publish or otherwise distribute
More informationContinuing Medical Education Post-Test
Continuing Medical Education Post-Test Based on the information presented in this monograph, please choose one correct response for each of the following questions or statements. Record your answers on
More informationPreven'ng AKI. Lessons from Contrast-associated AKI It s all about urine output
Preven'ng AKI Lessons from Contrast-associated AKI It s all about urine output CASE A 76 y/o male comes to the ED complaining of substernal crushing chest pain. The pain started a few hours ago while he
More informationManagement of Acute Kidney Injury in the Neonate. Carolyn Abitbol, M.D. University of Miami Miller School of Medicine / Holtz Children s Hospital
Management of Acute Kidney Injury in the Neonate Carolyn Abitbol, M.D. University of Miami Miller School of Medicine / Holtz Children s Hospital Objectives Summarize the dilemmas in diagnosing & recognizing
More informationIndications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014
Indications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014 Indications for cardiac catheterization Before a decision to perform an invasive procedure such
More informationACUTE KIDNEY INJURY. Stuart Linas U. Colorado SOM
ACUTE KIDNEY INJURY Stuart Linas U. Colorado SOM Marked increases in incidence of dialysis-requiring AKI in last decade JASN 24 37 2013 Question 1 Of patients who recover from an episode of AKI, what percentage
More informationDr.Nahid Osman Ahmed 1
1 ILOS By the end of the lecture you should be able to Identify : Functions of the kidney and nephrons Signs and symptoms of AKI Risk factors to AKI Treatment alternatives 2 Acute kidney injury (AKI),
More informationEVALUATION OF THE ROLE OF NEPHROTOXIC DRUGS IN CONTRAST INDUCED
EVALUATION OF THE ROLE OF NEPHROTOXIC DRUGS IN CONTRAST INDUCED NEPHROPATHY (CIN) Dr. SIRISHA.A POST GRADUATE KAMINENI INSTITUTE OF MEDICAL SCIENCES NARKETPALLY, TELANGANA INTRODUCTION Contrast-induced
More informationNational Imaging Associates, Inc. Clinical guidelines CARDIAC CATHETERIZATION -LEFT HEART CATHETERIZATION. Original Date: October 2015 Page 1 of 5
National Imaging Associates, Inc. Clinical guidelines CARDIAC CATHETERIZATION -LEFT HEART CATHETERIZATION CPT Codes: 93451, 93452, 93453, 93454, 93455, 93456, 93457, 93458, 93459, 93460, 93461 LCD ID Number:
More informationSection 4. CONTRAST INDUCED ACUTE KIDNEY INJURY
Section 4. CONTRAST INDUCED ACUTE KIDNEY INJURY Authors: Martin Gallagher, Vincent D Intini GUIDELINES a. We recommend using either iso-osmolar or low-osmolar iodinated contrast media, rather than high-osmolar
More informationAcute Coronary Syndrome (ACS) Patients with Chronic Kidney Disease being considered for Cardiac Catheterization. PROVINCIAL PROTOCOL March 2015
Acute Coronary Syndrome (ACS) Patients with Chronic Kidney Disease being considered for Cardiac Catheterization PROVINCIAL PROTOCOL March 2015 Contents Introduction.......................1 Assessing kidney
More informationThe ESC Registry on Chronic Ischemic Coronary Disease
EURObservational Research Programme The ESC Registry on Chronic Ischemic Coronary Disease Prof. Fausto J. Pinto, FESC, FACC, FASE, FSCAI Immediate Past-President, ESC University Hospital Sta Maria University
More informationQuality Payment Program: Cardiology Specialty Measure Set
Quality Payment Program: Cardiology Specialty Set Title Number CMS Reporting Method(s) Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for
More informationCan We Achieve Precision Solute Control with CRRT?
Can We Achieve Precision Solute Control with CRRT? Claudio Ronco, M.D. David Selewski, M.D. Rolando Claure-Del Granado, M.D. AKI & CRRT Conference February, 2019 Disclosures I have no actual or potential
More informationThe Triple Threat. Cardiac Care in the NT Annual Workshop 2017 is proudly supported by:
The Triple Threat DR KELUM PRIYADARSHANA FRACP CONSULTANT NEPHROLOGIST ROYAL DARWIN HOSPITAL Cardiac Care in the NT Annual Workshop 2017 is proudly supported by: Pathogenesis Diabetes CKD CVD Diabetic
More informationPercutaneous Mechanical Circulatory Support Devices
Percutaneous Mechanical Circulatory Support Devices Daniel Vazquez RN, RCIS Miami Cardiac & Vascular Institute FINANCIAL DISCLOSURES none CASE STUDY CASE STUDY 52 year old gentlemen Complaining of dyspnea
More information8/28/2018. Pre-op Evaluation for non cardiac surgery. A quick review from 2007!! Disclosures. John Steuter, MD. None
Pre-op Evaluation for non cardiac surgery John Steuter, MD Disclosures None A quick review from 2007!! Fliesheret al, ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and are for Noncardiac
More informationJinming Liu, 1 Yanan Xie, 1 Fang He, 2 Zihan Gao, 1 Yuming Hao, 1 Xiuguang Zu, 1 Liang Chang, 1 and Yongjun Li Introduction
BioMed Research International Volume 2016, Article ID 5985327, 7 pages http://dx.doi.org/10.1155/2016/5985327 Clinical Study Recombinant Brain Natriuretic Peptide for the Prevention of Contrast-Induced
More informationParis, August 28 th Gian Paolo Ussia on behalf of the CoreValve Italian Registry Investigators
Paris, August 28 th 2011 Is TAVI the definitive treatment in high risk patients? Impact Of Coronary Artery Disease In Elderly Patients Undergoing TAVI: Insight The Italian CoreValve Registry Gian Paolo
More informationImpact of Chronic Kidney Disease on Long-Term Outcome in Coronary Bypass Candidates Treated with Percutaneous Coronary Intervention
Original Article Print ISSN 1738-5520 On-line ISSN 1738-5555 Korean Circulation Journal Impact of Chronic Kidney Disease on Long-Term Outcome in Coronary Bypass Candidates Treated with Percutaneous Coronary
More informationCardio Renal Disease. Dr. Rajasekara Chakravarthi Head, Dept of Nephrology CARE Hospitals Hyderabad
Cardio Renal Disease Dr. Rajasekara Chakravarthi Head, Dept of Nephrology CARE Hospitals Hyderabad PREVALENCE OF CVD IS HIGH CAD LVH CHF (CLINICAL) (ECHO) (CLINICAL) GENERAL POPULATION 5-12% 20% 5% CKD
More informationTranscoronary Chemical Ablation of Atrioventricular Conduction
757 Transcoronary Chemical Ablation of Atrioventricular Conduction Pedro Brugada, MD, Hans de Swart, MD, Joep Smeets, MD, and Hein J.J. Wellens, MD In seven patients with symptomatic atrial fibrillation
More informationOvercoming the Cardiorenal Syndrome
Overcoming the Cardiorenal Syndrome October 29, 2016 Randall C Starling MD MPH FACC FESC FHFSA FHFA Professor of Medicine Heart & Vascular Institute Cleveland Clinic Lerner College of Medicine Cleveland
More informationClinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective
Clinical Seminar Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical
More informationAcetylcholine coronary spasm provocation testing: Revaluation in the real clinical practice
Research article Interventional Cardiology Acetylcholine coronary spasm provocation testing: Revaluation in the real clinical practice Background: Japanese Circulation Society guidelines for coronary spastic
More informationLM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More information